Specifically, mutant KRAS pancreatic cancer cells contain a CD133+/Mitohigh subpopulation of cells resistant to KRAS ablation that also exhibit enhanced mitochondrial metabolism and augmented OXPHOS dependency [55]. The gene discussed is KRAS; the disease is pancreatic neoplasm.